Voyager Transaction

Summary

On April 23, 2025, VERAXA Biotech AG and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH), announced that they have entered into a definitive business combination agreement.The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies. Upon closing of the transaction, VERAXA Biotech AG is expected to list on NASDAQ under the proposed ticker symbol “VERX.”

VISIT VOYAGER

View Management PresentAtion

VERAXA Biotech AG

Dr. Christoph Antz
‍Chief Executive Officer
antz@veraxa.com

Voyager Acquisition Corp.

Mr. Adeel Rouf
‍Chief Executive Officer, and Director
adeel@voyageracq.com
https://www.voyageracq.com

Valency Communications

For Media and Investors
Mario Brkulj
Valency Communications mbrkulj@valencycomms.eu

Press releases in connection with the Voyager transaction

View All

July 17, 2025

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

The filing of our Registration Statement marks a significant step forward in our path to accessing the public capital markets and vision of bringing the next generation of safe and highly effective cancer therapies to patients.

April 23, 2025

‍VERAXA and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies.